Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94:1623–40.

Article  CAS  PubMed  Google Scholar 

Schneider JL, Lin JJ, Shaw AT. ALK-positive lung cancer: a moving target. Nat Cancer. 2023;4:330–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Holla VR, Elamin YY, Bailey AM, Johnson AM, Litzenburger BC, Khotskaya YB, et al. ALK: a tyrosine kinase target for cancer therapy. Cold Spring Harb Mol Case Stud. 2017;3:a001115.

Article  PubMed  PubMed Central  Google Scholar 

Abdelaziz HM, Gaber M, Abd-Elwakil MM, Mabrouk MT, Elgohary MM, Kamel NM, et al. Inhalable particulate drug delivery systems for lung cancer therapy: nanoparticles, microparticles, nanocomposites and nanoaggregates. J Control Release. 2018;269:374–92.

Article  CAS  PubMed  Google Scholar 

Zou S, Tong Q, Liu B, Huang W, Tian Y, Fu X. Targeting STAT3 in cancer immunotherapy. Mol Cancer. 2020;19:145.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chuang TP, Lai WY, Gabre JL, Lind DE, Umapathy G, Bokhari AA, et al. ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression. Proc Natl Acad Sci USA. 2023;120:e2216479120.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu X, Li D, Liu J, Ma Z, Huang H, Min L, et al. Downregulation of PTPRK promotes cell proliferation and metastasis of NSCLC by enhancing STAT3 activation. Anal Cell Pathol. 2019;2019:4265040.

Article  Google Scholar 

Zhu H, Chang LL, Yan FJ, Hu Y, Zeng CM, Zhou TY, et al. AKR1C1 activates STAT3 to promote the metastasis of non-small cell lung cancer. Theranostics. 2018;8:676–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015;7:314ra185.

Article  PubMed  PubMed Central  Google Scholar 

Zheng Q, Dong H, Mo J, Zhang Y, Huang J, Ouyang S, et al. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics. 2021;11:824–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dong Y, Chen J, Chen Y, Liu S. Targeting the STAT3 oncogenic pathway: cancer immunotherapy and drug repurposing. Biomed Pharmacother. 2023;167:115513.

Article  CAS  PubMed  Google Scholar 

Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bharadwaj U, Kasembeli MM, Robinson P, Tweardy DJ. Targeting Janus kinases and signal transducer and activator of transcription 3 to treat inflammation, fibrosis, and cancer: rationale, progress, and caution. Pharmacol Rev. 2020;72:486–526.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li H, Zhu X, Sun Z, Wang Q, Song S, Xu Y, et al. Bruceine B displays potent antimyeloma activity by inducing the degradation of the transcription factor c-Maf. ACS Pharmacol Transl Sci. 2024;7:176–85.

Article  CAS  PubMed  Google Scholar 

Zhang Z, Tong J, Tang X, Juan J, Cao B, Hurren R, et al. The ubiquitin ligase HERC4 mediates c-Maf ubiquitination and delays the growth of multiple myeloma xenografts in nude mice. Blood. 2016;127:1676–86.

Article  CAS  PubMed  Google Scholar 

He YM, Zhou XM, Jiang SY, Zhang ZB, Cao BY, Liu JB, et al. TRIM25 activates AKT/mTOR by inhibiting PTEN via K63-linked polyubiquitination in non-small cell lung cancer. Acta Pharmacol Sin. 2022;43:681–91.

Article  CAS  PubMed  Google Scholar 

Scuto A, Krejci P, Popplewell L, Wu J, Wang Y, Kujawski M, et al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia. 2011;25:538–50.

Article  CAS  PubMed  Google Scholar 

Schust J, Sperl B, Hollis A, Mayer TU, Berg T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol. 2006;13:1235–42.

Article  CAS  PubMed  Google Scholar 

Desai A, Lovly CM. Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review. Transl Lung Cancer Res. 2023;12:615–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun J, Du Y, Song Q, Nan J, Guan P, Guo J, et al. E2F is required for STAT3-mediated upregulation of cyclin B1 and Cdc2 expressions and contributes to G2-M phase transition. Acta Biochim Biophys Sin. 2019;51:313–22.

Article  CAS  PubMed  Google Scholar 

Bosch-Barrera J, Queralt B, Menendez JA. Targeting STAT3 with silibinin to improve cancer therapeutics. Cancer Treat Rev. 2017;58:61–9.

Article  CAS  PubMed  Google Scholar 

Liang Q, Xia W, Li W, Jiao J. RNF20 controls astrocytic differentiation through epigenetic regulation of STAT3 in the developing brain. Cell Death Differ. 2018;25:294–306.

Article  CAS  PubMed  Google Scholar 

Cai H, Chen Y, Feng Y, Asadi M, Kaufman L, Lee K, et al. SARS-CoV-2 viral protein ORF3A injures renal tubules by interacting with TRIM59 to induce STAT3 activation. Mol Ther. 2023;31:774–87.

Article  CAS  PubMed  Google Scholar 

Cho JJ, Xu Z, Parthasarathy U, Drashansky TT, Helm EY, Zuniga AN, et al. Hectd3 promotes pathogenic Th17 lineage through Stat3 activation and Malt1 signaling in neuroinflammation. Nat Commun. 2019;10:701.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun X, Chen S, Zhao Y, Wu T, Zhao Z, Luo W, et al. OTUD6A in tubular epithelial cells mediates angiotensin II-induced kidney injury by targeting STAT3. Am J Physiol Cell Physiol. 2024;326:C400–13.

Article  CAS  PubMed  Google Scholar 

Du X, Pang J, Gu B, Si T, Chang Y, Li T, et al. A bio-orthogonal linear ubiquitin probe identifies STAT3 as a direct substrate of OTULIN in glioblastoma. Nucl Acids Res. 2023;51:1050–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang M, Han X, Yu T, Wang M, Luo W, Zou C, et al. OTUD1 promotes pathological cardiac remodeling and heart failure by targeting STAT3 in cardiomyocytes. Theranostics. 2023;13:2263–80.

Article  PubMed  PubMed Central  Google Scholar 

Ren Y, Zhao P, Liu J, Yuan Y, Cheng Q, Zuo Y, et al. Deubiquitinase USP2a sustains interferons antiviral activity by restricting ubiquitination of activated STAT1 in the nucleus. PLoS Pathog. 2016;12:e1005764.

Article  PubMed  PubMed Central  Google Scholar 

Harada D, Takigawa N, Kiura K. The role of STAT3 in non-small cell lung cancer. Cancers. 2014;6:708–22.

Article  CAS  PubMed  PubMed Central